Xbrane Biopharma AB (XBRANE) — Capital Reinvestment Ratio
Latest as of December 2024:
0.18x
Xbrane Biopharma AB (XBRANE) has a Capital Reinvestment Ratio of 0.18x as of December 2024, meaning it reinvests 0% of its operating cash flow (Skr93.91 Million) in capital expenditures (Skr17.30 Million). See Xbrane Biopharma AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.18x
Capex / Operating Cash Flow
Operating Cash Flow
Skr93.91 Million
SEK
Capital Expenditures
Skr17.30 Million
SEK
Data as of
Dec 2024
Most recent filing
Xbrane Biopharma AB Capital Reinvestment Ratio (2018–2018)
This chart tracks Xbrane Biopharma AB's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Xbrane Biopharma AB (2018–2018)
Year-by-year Capital Reinvestment Ratio for Xbrane Biopharma AB from 2018 to 2018. For live market cap and broader valuation context, see market cap of Xbrane Biopharma AB.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 0.03x | Skr46.71 Million | Skr1.60 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow